Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (27.1), the stock would be worth ¥3.98 (5% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 28.6 | ¥4.2 |
0%
|
| 3-Year Average | 27.1 | ¥3.98 |
-5%
|
| 5-Year Average | 30 | ¥4.4 |
+5%
|
| Industry Average | 25 | ¥3.67 |
-13%
|
| Country Average | 18.3 | ¥2.68 |
-36%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
|
8.7B CNY | 28.6 | -28.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 53 | 43.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 22.5 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 19.7 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 16.5 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 14.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.1 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 12.9 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 8.6 | 17.2 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Hunan Er-Kang Pharmaceutical Co Ltd
Glance View
Hunan Er-Kang Pharmaceutical Co., Ltd. engages in the research and development, production and sale of pharmaceutical products. The company is headquartered in Changsha, Hunan and currently employs 1,612 full-time employees. The company went IPO on 2011-09-27. The Company’s pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The firm distributes its products in domestic market and to overseas markets.
